{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:51:14Z","timestamp":1760403074768,"version":"build-2065373602"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR072571"],"award-info":[{"award-number":["P30 AR072571"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020853","name":"Spondyloarthritis Research and Treatment Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012495","name":"Spondylitis Association of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000980","name":"Arthritis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10067-025-07666-8","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:27:08Z","timestamp":1757622428000},"page":"4005-4013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis"],"prefix":"10.1007","volume":"44","author":[{"given":"Angela","family":"Achkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-2450","authenticated-orcid":false,"given":"Jean W.","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"7666_CR1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374:2563\u20132574. https:\/\/doi.org\/10.1056\/NEJMra1406182","journal-title":"N Engl J Med"},{"key":"7666_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V et al (2021) Psoriatic arthritis. Nat Rev Dis Primers 7:1\u201317. https:\/\/doi.org\/10.1038\/s41572-021-00293-y","journal-title":"Nat Rev Dis Primers"},{"key":"7666_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001450","volume":"7","author":"C L\u00f3pez-Medina","year":"2021","unstructured":"L\u00f3pez-Medina C, Molto A, Dougados M et al (2021) Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-perspa study. RMD Open 7:e001450. https:\/\/doi.org\/10.1136\/rmdopen-2020-001450","journal-title":"RMD Open"},{"key":"7666_CR4","doi-asserted-by":"publisher","first-page":"e002107","DOI":"10.1136\/rmdopen-2021-002107","volume":"8","author":"R Mazzucchelli","year":"2022","unstructured":"Mazzucchelli R, Mu\u00f1oz-Ortego J, Juanola X et al (2022) Trends in orthopaedic surgery for spondyloarthritis: outcomes from a National Hospitalised Patient Registry (MBDS) over a 17-year period (1999\u20132015). TREND-EspA study. RMD Open 8:e002107. https:\/\/doi.org\/10.1136\/rmdopen-2021-002107","journal-title":"RMD Open"},{"key":"7666_CR5","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2019-215313","volume":"78","author":"J Guldberg-M\u00f8ller","year":"2019","unstructured":"Guldberg-M\u00f8ller J, Cordtz RL, Kristensen LE, Dreyer L (2019) Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis 78:1517\u20131523. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215313","journal-title":"Ann Rheum Dis"},{"key":"7666_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS et al (2019) 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res 71:1285\u20131299. https:\/\/doi.org\/10.1002\/acr.24025","journal-title":"Arthritis Care Res"},{"key":"7666_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Smolen JS, Ramiro S et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 83:706\u2013719. https:\/\/doi.org\/10.1136\/ard-2024-225531","journal-title":"Ann Rheum Dis"},{"key":"7666_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2217\/imt-2023-0176","volume":"15","author":"JX Huang","year":"2023","unstructured":"Huang JX, Wei JC-C (2023) Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis? Immunotherapy 15:1195\u20131198. https:\/\/doi.org\/10.2217\/imt-2023-0176","journal-title":"Immunotherapy"},{"key":"7666_CR9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","volume":"42","author":"F Yang","year":"2023","unstructured":"Yang F, Lu C, Wang Y et al (2023) Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol 42:1593\u20131605. https:\/\/doi.org\/10.1007\/s10067-023-06529-4","journal-title":"Clin Rheumatol"},{"key":"7666_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030865","volume":"21","author":"T Gaber","year":"2020","unstructured":"Gaber T, Strehl C, Buttgereit F (2020) Impact of Janus kinase inhibition with tofacitinib on fundamental processes of bone healing. Int J Mol Sci 21:865. https:\/\/doi.org\/10.3390\/ijms21030865","journal-title":"Int J Mol Sci"},{"key":"7666_CR11","unstructured":"Merative (2024) Merative MarketScan Research Databases https:\/\/www.merative.com\/documents\/merative-marketscan-research-databases. Accessed 21 Dec 2024"},{"key":"7666_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/pds.3952","volume":"25","author":"M Dubreuil","year":"2016","unstructured":"Dubreuil M, Peloquin C, Zhang Y et al (2016) Validity of ankylosing spondylitis diagnoses in the health improvement network. Pharmacoepidemiol Drug Saf 25:399\u2013404. https:\/\/doi.org\/10.1002\/pds.3952","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7666_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/art.22682","volume":"57","author":"JA Singh","year":"2007","unstructured":"Singh JA, Holmgren AR, Krug H, Noorbaloochi S (2007) Accuracy of the diagnoses of spondylarthritides in veterans affairs medical center databases. Arthritis Rheum 57:648\u2013655. https:\/\/doi.org\/10.1002\/art.22682","journal-title":"Arthritis Rheum"},{"key":"7666_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3899\/jrheum.200453","volume":"48","author":"R Stovall","year":"2021","unstructured":"Stovall R, Peloquin C, Felson D et al (2021) Relation of NSAIDs, DMARDs, and TNF inhibitors for ankylosing spondylitis and psoriatic arthritis to risk of total hip and knee arthroplasty. J Rheumatol 48:1007\u20131013. https:\/\/doi.org\/10.3899\/jrheum.200453","journal-title":"J Rheumatol"},{"key":"7666_CR15","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.arth.2021.11.034","volume":"37","author":"TR Grace","year":"2022","unstructured":"Grace TR, Eralp I, Khan IA et al (2022) Are patients with end-stage arthritis willing to delay arthroplasty for payer-mandated physical therapy? J Arthroplasty 37:S27\u2013S31. https:\/\/doi.org\/10.1016\/j.arth.2021.11.034","journal-title":"J Arthroplasty"},{"issue":"7","key":"7666_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.18553\/jmcp.2018.24.7.623","volume":"24","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Adejoro O, Chastek B et al (2018) Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm 24(7):623. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.623","journal-title":"J Manag Care Spec Pharm"},{"key":"7666_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i969","volume":"352","author":"N Pearce","year":"2016","unstructured":"Pearce N (2016) Analysis of matched case\u2013control studies. BMJ 352:i969. https:\/\/doi.org\/10.1136\/bmj.i969","journal-title":"BMJ"},{"key":"7666_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2217\/imt-2023-0032","volume":"15","author":"N George","year":"2023","unstructured":"George N, Liew JW, Dubreuil M (2023) The role of upadacitinib for the treatment of axial spondyloarthritis. Immunotherapy 15:1227\u20131237. https:\/\/doi.org\/10.2217\/imt-2023-0032","journal-title":"Immunotherapy"},{"key":"7666_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030270","volume":"15","author":"E Toussirot","year":"2022","unstructured":"Toussirot E (2022) The use of Janus kinase inhibitors in axial spondyloarthritis: current insights. Pharmaceuticals 15:270. https:\/\/doi.org\/10.3390\/ph15030270","journal-title":"Pharmaceuticals"},{"key":"7666_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001374","volume":"6","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Sepriano A, Smolen JS et al (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open 6:e001374. https:\/\/doi.org\/10.1136\/rmdopen-2020-001374","journal-title":"RMD Open"},{"key":"7666_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Kato K, Magrey M et al (2021) Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 384:1227\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa2022516","journal-title":"N Engl J Med"},{"key":"7666_CR22","doi-asserted-by":"publisher","unstructured":"Fragoulis GE, Siebert S (2024) Treatment strategies in axial spondyloarthritis: what, when and how? https:\/\/doi.org\/10.1093\/rheumatology\/keaa435. Accessed 14 Dec 2024","DOI":"10.1093\/rheumatology\/keaa435"},{"key":"7666_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43166-022-00128-y","volume":"49","author":"Y El Miedany","year":"2022","unstructured":"El Miedany Y, Palmer D, Wassif G et al (2022) Psoriatic arthritis treatment to the target: a consensus, evidence-based clinical practice recommendations for the management of psoriatic arthritis and its concomitant clinical manifestations. Egypt Rheumatol Rehabil 49:32. https:\/\/doi.org\/10.1186\/s43166-022-00128-y","journal-title":"Egypt Rheumatol Rehabil"},{"key":"7666_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","volume":"19","author":"W Bautista-Molano","year":"2023","unstructured":"Bautista-Molano W, Berman A, Burgos-Vargas R et al (2023) Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol 19:724\u2013737. https:\/\/doi.org\/10.1038\/s41584-023-01034-z","journal-title":"Nat Rev Rheumatol"},{"key":"7666_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4081\/reumatismo.2004.169","volume":"56","author":"L De Filippis","year":"2004","unstructured":"De Filippis L, Candeloro C, Salaffi F et al (2004) Epidemiology and risk factors in osteoarthritis: literature review data from \u2018OASIS\u2019 study. Reumatismo 56:169\u2013184. https:\/\/doi.org\/10.4081\/reumatismo.2004.169","journal-title":"Reumatismo"},{"key":"7666_CR26","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/rheumatology\/key424","volume":"58","author":"S Hawley","year":"2019","unstructured":"Hawley S, Cordtz R, Dreyer L et al (2019) Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. Rheumatology 58:1168\u20131175. https:\/\/doi.org\/10.1093\/rheumatology\/key424","journal-title":"Rheumatology"},{"key":"7666_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.semarthrit.2017.09.006","volume":"47","author":"S Hawley","year":"2018","unstructured":"Hawley S, Cordtz R, Dreyer L et al (2018) Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: an interrupted time-series analysis. Semin Arthritis Rheum 47:605\u2013610. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.006","journal-title":"Semin Arthritis Rheum"},{"key":"7666_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.semarthrit.2013.01.002","volume":"43","author":"KJ Aaltonen","year":"2013","unstructured":"Aaltonen KJ, Joensuu JT, Virkki LM et al (2013) Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. Semin Arthritis Rheum 43:55\u201362. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.01.002","journal-title":"Semin Arthritis Rheum"},{"key":"7666_CR29","first-page":"2409","volume":"28","author":"P Gordon","year":"2001","unstructured":"Gordon P, West J, Jones H, Gibson T (2001) A 10 year prospective followup of patients with rheumatoid arthritis 1986\u201396. J Rheumatol 28:2409\u20132415","journal-title":"J Rheumatol"},{"key":"7666_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633\u20131644. https:\/\/doi.org\/10.1001\/jama.296.13.jrv60011","journal-title":"JAMA"},{"key":"7666_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086. https:\/\/doi.org\/10.1136\/bmj.c7086","journal-title":"BMJ"},{"key":"7666_CR32","unstructured":"Jafarzadeh S, Neogi T, Felson D (2021) Long-term effect of prescription non-steroidal anti-inflammatory drug regular use on the risk of a knee replacement [abstract]. Arthritis Rheumatol. 73 (suppl 9). https:\/\/acrabstracts.org\/abstract\/long-term-effect-of-prescription-non-steroidal-anti-inflammatory-drug-regular-use-on-the-risk-of-a-knee-replacement\/. Accessed 18 Apr 2024"},{"key":"7666_CR33","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1038\/s41598-024-56665-3","volume":"14","author":"Z Salis","year":"2024","unstructured":"Salis Z, Sainsbury A (2024) Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5 years. Sci Rep 14:6593. https:\/\/doi.org\/10.1038\/s41598-024-56665-3","journal-title":"Sci Rep"},{"key":"7666_CR34","unstructured":"Hsu H, Siwiec RM (2024) Knee osteoarthritis. In: StatPearls. StatPearls Publishing, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507884\/. Accessed 20 Aug 2024"},{"key":"7666_CR35","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","volume":"58","author":"PC Taylor","year":"2019","unstructured":"Taylor PC (2019) Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology 58:i17\u2013i26. https:\/\/doi.org\/10.1093\/rheumatology\/key225","journal-title":"Rheumatology"},{"key":"7666_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031246","volume":"23","author":"L T\u00f3th","year":"2022","unstructured":"T\u00f3th L, Fazekas E, V\u00e1ncsa A et al (2022) Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients. Int J Mol Sci 23:1246. https:\/\/doi.org\/10.3390\/ijms23031246","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07666-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:24:16Z","timestamp":1760365456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07666-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7666"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07666-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angela Achkar, Christine Peloquin, and Jean W. Liew declare no competing interests. Maureen Dubreuil is a member of advisory board for Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}